NEURO-BIO LTD HAS BEEN GRANTED A TECNIOSPRING INDUSTRY AWARD 2021
Neuro-Bio has been awarded a Tecniospring INDUSTRY award together with the Catalan CRO, Xenopat (www.xenopat.com ) to develop a new antitumor drug and / or antimetastatic drug based on the inhibition of the T14 peptide in metastatic colorectal cancer. Tecniospring INDUSTRY (http://catalonia.com/innovate-in-catalonia/tecniospringplus/) offers financial support to cover up to 100% of 2-year employment contracts and develop research activity. Tecniospring is a MSCA CO-FUND with Catalan Companies, which are TECNIO entities, and the Marie Skłodowska Curie (H2020) foundation supporting cooperation between industry and academia and innovative training to enhance employability and career development. Dr Marta Tellez with extensive expertise in the cancer and metastasis field has been selected to develop this collaboration between Neuro-Bio and Xenopat.Upon completion of this 2-year project, Xenopat aims to establish whether the new T14 inhibitor is effective for treating metastatic CRC and thus worth continuing the co-development of the new drug to the clinics.
NEURO-BIO LTD HAS BEEN ACCEPTED IN THE RISING UP IN SPAIN PROGRAM
Neuro-Bio Ltd project has been selected in the top 15 applicants out of 350, following the evaluation conducted by our Panel of Experts of the Rising Up Spain program (https://www.investinspain.org/en/we-help-you/rising-up-in-spain). Rising Up in Spain supports foreign startups setting up in Spain and makes all phases of the process developing entrepreneurial projects in the country easy. This program provides access to work space and to a broad network of investors. Neuro-Bio has already opened a virtual office in Spain and together with this program looks forward to promote and extend the Spanish collaborations.